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ABSTRACT
Background: Certolizumab pegol is a PEGylated tumour
necrosis factor inhibitor.
Objective: To evaluate the efficacy and safety of
certolizumab pegol versus placebo, plus methotrexate
(MTX), in patients with active rheumatoid arthritis (RA).
Methods: An international, multicentre, phase 3,
randomised, double-blind, placebo-controlled study in
active adult-onset RA. Patients (n=619) were rando-
mised 2:2:1 to subcutaneous certolizumab pegol (liquid
formulation) 400 mg at weeks 0, 2 and 4 followed by
200 mg or 400 mg plus MTX, or placebo plus MTX, every
2 weeks for 24 weeks. The primary end point was ACR20
response at week 24. Secondary end points included
ACR50 and ACR70 responses, change from baseline in
modified Total Sharp Score, ACR core set variables and
physical function.
Results: Significantly more patients in the certolizumab
pegol 200 mg and 400 mg groups achieved an ACR20
response versus placebo (p(0.001); rates were 57.3%,
57.6% and 8.7%, respectively. Certolizumab pegol 200
and 400 mg also significantly inhibited radiographic
progression; mean changes from baseline in mTSS at
week 24 were 0.2 and 20.4, respectively, versus 1.2 for
placebo (rank analysis p(0.01). Certolizumab pegol-
treated patients reported rapid and significant improve-
ments in physical function versus placebo; mean changes
from baseline in HAQ-DI at week 24 were 20.50 and
20.50, respectively, versus 20.14 for placebo
(p(0.001). Most adverse events were mild or moderate,
with low incidence of withdrawals due to adverse events.
Five patients developed tuberculosis.
Conclusion: Certolizumab pegol plus MTX was more
efficacious than placebo plus MTX, rapidly and signifi-
cantly improving signs and symptoms of RA and physical
function and inhibiting radiographic progression.
Trial registration number: NCT00175877
Tumour necrosis factor (TNF) has a central role in
the pathogenesis of rheumatoid arthritis (RA),
mediating both inflammation and joint damage.
1–3
TNF inhibitors revolutionised the management of
RA because these agents improve signs and symp-
toms and physical function and inhibit structural
damage, particularly in combination with metho-
trexate (MTX).
4–7 All three TNF inhibitors in clinical
use (infliximab, adalimumab and etanercept) have
shown similar efficacy in randomised controlled
clinical trials.
8–12 These agents all contain an immu-
noglobulin G Fc region which extends their half-life
in circulation.
13
Certolizumab pegol is a PEGylated Fab9 frag-
ment of a humanised anti-TNF antibody with high
affinity to TNF. It lacks an Fc region and may thus
avoid potential Fc-mediated effects such as com-
plement- or antibody-dependent, cell-mediated
cytotoxicity, which have been seen in vitro, and
attachment of the PEG moiety to the Fab9
fragment yields a molecule with a plasma half-life
of about 2 weeks.
14 Certolizumab pegol is effective
in the treatment of Crohn’s disease,
15 16 and has
been shown to significantly improve the signs and
symptoms of active RA in phase 2
17 and phase 3
18
trials. This study, Rheumatoid Arthritis PreventIon
of structural Damage 2 (RAPID 2), evaluated the
efficacy and safety of subcutaneous liquid certoli-
zumab pegol (200 mg and 400 mg) plus MTX
every 2 weeks compared with placebo plus MTX in
patients with active RA despite >6 months’ MTX
treatment.
PATIENTS AND METHODS
Design overview
RAPID 2 was a 24-week, phase 3, double-blind,
randomised, multicentre, placebo-controlled study at
76 international sites (June 2005 to September 2006).
Patients were randomised 2:2:1 to one of two
regimens of subcutaneous liquid certolizumab pegol
(400 mg at weeks 0, 2 and 4, followed by 200 or
400 mg every2 weeks)plus MTX, or placebo (saline)
plus MTX. The study was conducted in accordance
with good clinical practice and the Declaration of
Helsinkiandwasapprovedbyaninstitutionalreview
committee at each participating centre. All partici-
pating patients provided written informed consent.
Patients who did not show an ACR20 response
at both weeks 12 and 14 were to be withdrawn
from the study, designated ACR20 non-responders
in the primary analysis and allowed to enter an
open-label extension study at week 16 with
certolizumab pegol 400 mg every 2 weeks.
Participants
The full inclusion and exclusion criteria are available
online as supplementary material. Eligible patients
were aged >18 years with a diagnosis of RA, defined
by American College of Rheumatology (ACR) 1987
criteria,
19 of >6 months’ duration but not longer
than 15 years, with active disease at screening and
baseline. Patients had to have received prior MTX
for >6 months (stable dose >10 mg/week for
>2 months before baseline).
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agent for RA within 6 months before enrolment (3 months for
etanercept and anakinra), had received previous treatment with
a biological agent resulting in a severe hypersensitivity or
anaphylactic reaction, or had not initially responded to previous
anti-TNF therapy. Oral corticosteroids ((10 mg/day predni-
sone equivalent) and non-steroidal anti-inflammatory drugs and
cyclo-oxygenase-2 inhibitors were permitted provided that the
doses were stable within 28 and 14 days of baseline, respectively
and remained stable during the study.
Patients with history of, or positive chest x-ray findings for,
tuberculosis, or a positive purified protein derivative (PPD) skin
test (defined as positive indurations per local medical practice)
were excluded. As per protocol, if a positive PPD skin test was
assumed by the local investigators to be related to previous
bacille Calmette–Gue ´rin (BCG) vaccination and was not
associated with clinical or radiographic suspicion of tubercu-
losis, patients could be enrolled at the discretion of the
investigator. In total, 101 patients (16%) were enrolled with a
PPD test >5 mm at baseline.
Outcomes and follow-up: clinical response
Assessments were made at baseline, weeks 1, 2, 4, 6, 8, 12, 14, 20
and 24, or withdrawal. The primary end point was ACR20
response at week 24, defined as a decrease of >20% from
baseline in the number of tender (n=68) and swollen (n=66)
joints, plus a 20% improvement in three or more of the
following: patient’s and physician’s global assessment of disease
activity, patient’s assessment of arthritic pain, Health
Assessment Questionnaire-Disability Index (HAQ-DI) and
serum C-reactive protein or erythrocyte sedimentation rate
(ESR).
20 Secondary efficacy end points at week 24 included
ACR50, ACR70, mean change from baseline in van der Heijde-
modified Total Sharp Scores (mTSS),
21 22 Short Form-36 (SF-36)
Health Survey,
23 and individual ACR core set variables. Disease
activity was assessed using the Disease Activity Score 28-joint
assessment 4 (DAS28 (ESR)4).
Assessment of physical function and health-related quality of life
Physical function was assessed using the HAQ-DI
24 at each visit.
Health-related quality of life was assessed using the SF-36
Health Survey
23 physical component summary (PCS), mental
component summary (MCS) and physical functioning (PF)
domain scores at weeks 0, 12 and 24 or withdrawal. Minimal
clinically important differences (MCID) were defined as a
decrease of >0.22 points from baseline in the HAQ-DI and
improvements >2.5–5.0 in the PCS and MCS and >5.0–10.0 in
PF scores.
25 26
Radiographic evaluations
Radiographic assessments of hands and feet were performed at
baseline and at week 24 or withdrawal using the van der Heijde
mTSS, which quantifies erosions (erosion score (ES)) and joint
space narrowing (JSN).
21 22 Radiographs were read centrally and
blinded (for treatment, visit and patient identification) and
independently by two experienced readers. The mean score of
two readers was used for analyses.
Safety assessments
Safety was assessed at all visits, from screening through follow-
up visits 12 weeks after the last dose for patients who did not
enter the open-label extension phase.
Statistical analysis
Sample size was determined on expected differences in the
ACR20 responder rate between certolizumab pegol and placebo
at week 24. Five hundred and ninety randomised patients would
provide 90% power to detect a difference of >20% in ACR20
response at week 24 between each certolizumab pegol group
and placebo at a two-sided significance level of a=0.025,
assuming a placebo rate of 30%.
Efficacy analyses were conducted on the intention-to-treat
(ITT) population (all randomised patients). Primary analysis
used non-responder imputation; patients who received rescue
Figure 1 Patient disposition. *Two
patients in the placebo treatment group
received CZP and are included in the
200 mg group for safety evaluations. CZP,
certolizumab pegol; ITT, intention-to-treat;
MTX, methotrexate.
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other than MTX, any other biological agent, intravenous
corticosteroids, or intra-articular hyaluronic acid) or withdrew
for any reason were considered non-responders from that time
point onward. The number of subjects in the summaries varies
slightly from the ITT numbers owing to non-imputable missing
data. Treatment comparisons for the certolizumab pegol groups
with placebo were performed using logistic regression with
factors for treatment and region. Treatment effects were
estimated with odds ratios and 97.5% confidence intervals
(CIs) obtained by fitting this model. p Values of these treatment
effects were also calculated (Wald test). To control the type I
error rate further at 5%, a closed test procedure
27 was used.
Safety analyses were conducted on the safety population (all
patients who received treatment).
Treatment comparisons for change from baseline at week 24
in individual ACR core set components were analysed using
analysis of covariance with last observation carried forward
(LOCF) imputation, with region and treatment group as factors
and baseline value as covariate. Mean change from baseline
mTSS was analysed using analysis of covariance on the ranks,
with treatment and region as factors and rank baseline mTSS as
covariate. mTSS at week 24 for early withdrawals was
estimated by linear extrapolation of the last available value to
week 24, assuming disease progression occurred at the same rate
between weeks 0 and withdrawal.
Sensitivity analyses were performed under various assump-
tions on the imputation of missing values, including LOCF
imputation of missing scores.
RESULTS
Patient characteristics and disposition
Six hundred and nineteen patients were randomised (ITT
population); 246 each to certolizumab pegol 200 mg and
400 mg and 127 to placebo. Only 17 (13.4%) placebo patients
completed the study versus 174 (70.7%) and 181 (73.6%) in the
certolizumab pegol 200 mg and 400 mg groups, respectively.
More placebo-treated patients (79.5%; n=101) discontinued
treatment owing to lack of ACR20 response at week 16 versus
certolizumab pegol 200 mg (19.9%; n=49) and 400 mg (18.7%;
n=46) (fig 1). Of these, all except one patient from the placebo
group entered the open-label extension study.
Patient demographics and baseline characteristics were
similar in the three treatment groups and indicated high
baseline disease activity (table 1). Baseline demographics were
also similar among patients who withdrew at week 16.
Table 1 Patient demographics and arthritis status at baseline (ITT population)
Characteristics
Placebo + MTX
(n=127)
Certolizumab pegol
200 mg + MTX
(n=246)
Certolizumab pegol
400 mg + MTX
(n=246)
Demographics
Age (years), mean (SD) 51.5 (11.8) 52.2 (11.1) 51.9 (11.8)
Female, n (%) 107 (84.3) 206 (83.7) 192 (78.0)
Disease duration (years), mean (SD) 5.6 (3.9) 6.1 (4.1) 6.5 (4.3)
No of prior DMARDs (excluding MTX), mean (SD) 1.2 (1.2) 1.2 (1.3) 1.3 (1.2)
MTX (mg/week), mean (SD) 12.2 (3.3) 12.5 (3.6) 12.6 (3.7)
Steroid use, n (%) 76 (59.8) 136 (55.3) 152 (61.8)
Previous anti-TNF use, n (%)* 2 (1.6) 4 (1.6) 2 (0.8)
ACR core components
No of tender joints (0–68), mean (SD) 30.4 (13.4) 30.1 (14.5) 30.0 (13.9)
No of swollen joints (0–66), mean (SD) 21.9 (9.7) 20.5 (9.6) 21.0 (10.2)
Physician’s global assessment of arthritis (mm), mean
(SD)
65.7 (15.1) 64.3 (14.6) 62.8 (14.0)
Patient’s global assessment of arthritis (mm), mean (SD) 59.9 (21.9) 62.4 (20.4) 61.1 (19.6)
Patient’s assessment of arthritic pain (mm), mean (SD) 59.9 (22.2) 61.8 (19.3) 60.5 (20.0)
CRP (mg/l), geometric mean (CV){ 13.5 (185.8) 14.2 (190.8) 13.1 (169.9)
ESR (mm/h), geometric mean (CV) 40.8 (45.2) 43.7 (41.4) 39.1 (40.2)
HAQ-DI, mean (SD) 1.6 (0.6) 1.6 (0.6) 1.6 (0.6)
Duration of morning stiffness (h), median (range) 2.0 (0 to 24.0) 2.0 (0 to 24.0) 2.0 (0 to 24.0)
Rheumatoid factor
RF positive (>14 IU/ml), n (%) 97 (78.2) 186 (77.5) 179 (75.5)
RF plasma concentration (IU/ml), mean (SD) 135.4 (179.6) 145.3 (232.7) 149.4 (245.5)
x-Ray progression
Estimated yearly progression{ (mTSS/year) 8.7 6.6 7.4
mTSS, mean (SD) 46.5 (58.6) 39.6 (50.1) 46.7 (56.0)
ES, mean (SD) 23.1 (32.1) 19.0 (26.8) 21.6 (29.7)
JSN, mean (SD) 23.4 (27.7) 20.6 (24.4) 25.1 (28.1)
Disease activity (DAS28 (ESR)), mean (SD) 6.83 (0.87) 6.85 (0.84) 6.80 (0.79)
*Only 2 patients (both in the CZP 200 mg + MTX group) were previously treated with two or more anti-TNF agents; {normal 0–
6 mg/l; {baseline mean mTSS divided by mean duration of rheumatoid arthritis.
ACR, American College of Rheumatology; CRP, C-reactive protein; CV, coefficient of variation; CZP, certolizumab pegol;
DAS28(ESR), Disease Activity Score 28; DMARD, disease-modifying antirheumatic drug; ES, erosion score; ESR, erythrocyte
sedimentation rate; HAQ-DI, Health Assessment Questionnaire-Disability Index; ITT, intention-to-treat; JSN, joint space narrowing;
mTSS, modified Total Sharp Scores; MTX, methotrexate; RF, rheumatoid factor; TNF, tumour necrosis factor.
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Ann Rheum Dis 2009;68:797–804. doi:10.1136/ard.2008.101659 799Figure 2 ACR responder rates at week 24 (ITT population—non-responder imputation) and change from baseline in disease signs and symptoms over
time (ITT population). (A) *p,0.001 versus placebo; {p(0.01 versus placebo relate to comparison of odds ratios (ORs) from logistic regression with
treatment and region as factors; {OR=14.4 (97.5% CI 6.7 to 31.0); 1OR=14.8 (95% CI 5.3 to 41.6); "OR=23.8 (95% CI 3.2 to 175.9); **OR=14.3
(97.5% CI 6.7 to 30.8); {{OR=15.3 (95% CI 5.5 to 42.9); {{OR=15.5 (95% CI 2.1 to 115.4). (B) *p,0.001 versus placebo; {p(0.01 versus placebo;
{p(0.05 versus placebo. (C–E) *p,0.001 versus placebo using ANCOVA with treatment and region as factors and baseline as covariate. LOCF.
ACR, American College of Rheumatology; CI, confidence interval; CZP, certolizumab pegol; DAS28 (ESR), Disease Activity Score 28 (erythrocyte
sedimentation rate); HAQ-DI, Health Assessment Questionnaire-Disability Index; ITT, intention-to-treat; LOCF, last observation carried forward;
LS, least squares; MTX, methotrexate.
Extended report
800 Ann Rheum Dis 2009;68:797–804. doi:10.1136/ard.2008.101659Clinical efficacy
Differences in ACR20 responses at week 24 were significant for
certolizumab pegol 200 mg and 400 mg plus MTX, respectively,
versus placebo plus MTX (fig 2A; p(0.001; response rates:
57.3%, 57.6% and 8.7%, respectively), as were differences in
ACR50 and ACR70 responses (fig 2A; p(0.01).
Certolizumab pegol conferred rapid improvement in the signs
and symptoms of RA. Significantly higher ACR20 responses
were seen with certolizumab pegol as early as week 1, increased
over the first 12 weeks and were maintained through week 24
(fig 2B; p(0.01). ACR50 and ACR70 responses were signifi-
cantly higher by weeks 6 and 20, respectively (fig 2B; p(0.01).
Certolizumab pegol conferred improvements in all ACR core
components versus placebo (table 2), including significant
reductions in swollen (fig 2C) and tender joint counts (data
not shown) by week 1, with continued improvement to week
24. A significant proportion of the total effect of certolizumab
pegol was seen by week 4 (table 2).
Treatment with certolizumab pegol plus MTX was also
associated with significantly greater improvement in DAS28
(ESR) from baseline versus placebo at all time points (p,0.001;
fig 2D). At week 24, mean (SD) change was: 200 mg, –2.27
(1.38); 400 mg, –2.46 (1.31); placebo, 20.50 (1.05). DAS28
remission (DAS28 ,2.6) was seen in 9.4% or 8.5% of patients
treated with certolizumab pegol 200 mg or 400 mg, respec-
tively, at week 24, compared with 0.8% of patients treated in
the placebo group (p(0.05 vs placebo).
Physical function and health-related quality of life
Significantly more certolizumab pegol-treated patients reported
significant improvements in physical function (HAQ-DI) versus
placebo from week 1 to week 24 (p,0.001; fig 2E) and clinically
meaningful improvements in physical function (HAQ-DI
MCID) from weeks 2 to 24. By week 24, 57% and 53% of
patients in the certolizumab pegol 200 mg and 400 mg groups,
respectively, achieved HAQ-DI MCID versus 11% of placebo
patients (p,0.001). Patients receiving certolizumab pegol also
reported significantly greater improvements in SF-36 PCS, MCS
and PF domain scores versus placebo at weeks 12 and 24
(p,0.001). At week 24, adjusted mean changes from baseline in
PCS were 5.2 and 5.5 for certolizumab pegol 200 and 400 mg,
respectively, versus 0.9 for placebo and in PF domain scores were
12.1 and 12.4, respectively, versus 0.6 for placebo (p,0.001).
Sensitivity analyses of clinical and radiographic efficacy,
physical function and health-related quality of life, including
LOCF, confirmed the main analyses (data not shown).
Radiographic progression
Mean changes from baseline to week 24 in mTSS were
significantly less in patients treated with certolizumab pegol
200 mg (0.2; 95% CI 20.1 to 0.6) and 400 mg (20.4; 95% CI
20.7 to 20.1) plus MTX versus placebo plus MTX (1.2; 95% CI
0.5 to 2.0) (fig 3A, left graph; p(0.01 (200 mg) and p(0.001
(400 mg) by rank analysis). The negative CI for the certolizu-
mab pegol 400 mg group suggests that some repair may have
occurred.
28 Mean changes from baseline in ES were 0.1 (95% CI
20.1 to 0.4) and 20.3 (95% CI 20.6 to 20.1) with certolizumab
pegol 200 mg and 400 mg, respectively, versus placebo (0.7; 95%
CI 0.3 to 1.2) (p(0.01 (200 mg), p,0.001 (400 mg) by rank
analysis) (fig 3B). Mean changes from baseline in JSN for
certolizumab pegol 200 mg and 400 mg were 0.1 (95% CI 20.1
to 0.3) and 20.1 (95% CI 20.2 to 0.0), respectively, versus 0.5
(95% CI 0.1 to 0.9) for placebo (p(0.01 by rank analysis; fig 3B).
The cumulative probability plots at week 24 show that more
patients in the placebo plus MTX group show progression, and
Table 2 Adjusted mean change and mean percentage improvement from baseline in ACR core components at weeks 4 and 24 (ITT population—
LOCF)
ACR core components
Week 4 Week 24
Placebo + MTX
(n=127)
Certolizumab
pegol 200 mg +
MTX
(n=246)
Certolizumab
pegol 400 mg +
MTX
(n=246)
Placebo + MTX
(n=127)
Certolizumab
pegol 200 mg +
MTX
(n=246)
Certolizumab
pegol 400 mg +
MTX
(n=246)
Swollen joint count
Adjusted mean change (SE) –1.4 (0.6) –9.1 (0.5) –8.9 (0.5) –2.7 (0.7) –13.8 (0.5) –14.2 (0.5)
Mean percentage improvement (SD) 7.6 (28.0) 41.7 (32.8) 41.4 (30.7) 13.3 (43.1) 64.2 (35.9) 67.8 (29.0)
Tender joint count
Adjusted mean change (SE) –1.8 (0.9) –10.7 (0.6) –11.3 (0.7) –3.8 (1.0) –17.3 (0.8) –19.5 (0.8)
Mean percentage improvement (SD) 4.4 (27.8) 33.4 (40.7) 36.0 (29.1) 10.5 (40.4) 54.8 (45.3) 63.6 (29.2)
Physician’s global assessment of arthritis
Adjusted mean change (SE) –6.5 (1.4) –24.1 (1.1) –21.9 (1.1) –9.2 (1.7) –34.8 (1.3) –35.6 (1.3)
Mean percentage improvement (SD) 5.7 (26.4) 34.3 (24.4) 30.1 (25.0) 12.0 (30.6) 52.3 (28.1) 52.1 (29.2)
Patient’s global assessment of arthritis
Adjusted mean change (SE) –2.9 (1.7) –14.6 (1.2) –15.9 (1.3) –4.2 (2.0) –24.5 (1.4) –26.6 (1.5)
Mean percentage improvement (SD) –8.5 (63.3) 18.1 (57.3) 22.4 (32.2) –5.8 (61.9) 34.2 (46.6) 39.3 (37.4)
Patient’s assessment of arthritic pain
Adjusted mean change (SE) –2.8 (1.6) –14.0 (1.2) –14.9 (1.2) –4.7 (1.9) –23.7 (1.4) –26.1 (1.4)
Mean percentage improvement (SD) –8.5 (59.3) 21.0 (29.9) 18.5 (55.1) –8.3 (77.4) 35.9 (34.9) 37.9 (38.5)
HAQ-DI
Adjusted mean change (SE) 20.05 (0.03) 20.27 (0.03) 20.28 (0.03) 20.14 (0.04) 20.50 (0.03) 20.50 (0.03)
Mean percentage improvement (SD) –3.7 (54.6) 18.2 (26.5) 16.8 (34.3) 3.7 (59.4) 31.8 (38.5) 32.0 (35.1)
CRP, adjusted geometric mean (95% CI) –
ratio to baseline
0.89 (0.74 to 1.08) 0.34 (0.30 to 0.40) 0.36 (0.31 to 0.42) 0.92 (0.74 to 1.14) 0.42 (0.35 to 0.49) 0.34 (0.29 to 0.40)
p,0.001 for certolizumab pegol 200 mg and 400 mg versus placebo for all ACR core components at weeks 4 and 24 based on adjusted mean change from baseline (ANCOVA with
LOCF imputation with region and treatment group as factors and baseline value as covariate).
ACR, American College of Rheumatology; ANCOVA, analysis of covariance; CI, confidence interval; CRP, C-reactive protein; HAQ-DI, Health Assessment Questionnaire-Disability
Index; ITT, intention-to-treat; LOCF, last observation carried forward; MTX, methotrexate.
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pegol plus MTX (supplementary fig 1, online only).
In addition, for patients who withdrew at week 16, there was
significantly less radiographic progression in certolizumab
pegol-treated patients (combined data) than with placebo
(fig 3A, right graph). Post hoc linear extrapolation of the week
16 radiographic data suggests that a significant treatment
difference would also have been seen at week 24.
Safety
Owing to the higher rate of ACR20 non-responders at week 16
in the placebo group, mean treatment exposure was longer in
the certolizumab pegol groups than the placebo group. Adverse
events occurred in 52.8%, 56.0% and 50.8% of patients in the
placebo, certolizumab pegol 200 mg and 400 mg groups,
respectively; most were mild/moderate in intensity (table 3).
The most frequently reported adverse events included urinary
tract infection, haematuria and bacteriuria for placebo; urinary
tract infection, upper respiratory tract infection and headache
for certolizumab pegol 200 mg; and hypertension and headache
for certolizumab pegol 400 mg (table 3). Adverse event
reporting of hypertension was at the discretion of the
investigator and no preset guidelines were defined. Post hoc
analysis showed that hypertensive events were related to
previous hypertensive status, were transitory and were not
related to the study injection.
One case (0.4%) of lupus erythematosus rash with certolizu-
mab pegol 200 mg occurred. No injection-site reactions or pain
(Medical Dictionary for Regulatory Activities (MedDRA) coded)
werereportedforplacebo.Therewere3(1.2%)or5(2.0%)casesof
injection-site reactions and 0 or 1 (0.4%) case of injection-site pain
in the certolizumab pegol 200 mg or 400 mg groups, respectively.
Adverse events leading to discontinuation of the study drug were
1.6% for placebo and 4.8% and 2.8% for certolizumab pegol
200 mg and 400 mg, respectively. Anti-certolizumab pegol anti-
bodies were detected in 5.1% of patients receiving certolizumab
pegol plus MTX. The number of antibody-positive patients was
too low to identify any statistically or clinically significant
antibody effect on response. Nine patients had neutralising
antibodies: 5 (2.0%) in the certolizumab pegol 200 mg group
and 4 (1.6%) in the 400 mg group.
The incidence of serious adverse events was 3.2% for placebo
and 7.3% in each certolizumab pegol group. Serious infections
occurred in 0%, 3.2% and 2.4% in the placebo, certolizumab pegol
200 mg and 400 mg groups, respectively. Serious infections
included one case each of erysipelas, disseminated tuberculosis,
peritoneal tuberculosis, pulmonary tuberculosis, gastroenteritis,
postoperative wound infection, tooth abscess and urosepsis with
certolizumab pegol 200 mg and one case each of erysipelas,
pneumonia and upper respiratory tract infection and two cases
each of sinusitis and tuberculosis with 400 mg. Five patients in
the certolizumab pegol arms developed tuberculosis: three from
Figure 3 Change from baseline in mTSS, ES and JSN at week 24 (ITT population—linear extrapolation). (A) *p,0.001; {p(0.01; {p(0.05 versus
placebo (ANCOVA on ranks with treatment and region as factors and rank baseline as covariate). Lehmann point estimate of shift (95% CI): 120.3
(20.8 to 0.0); "20.7 (21.0 to 0.0). (B) *p,0.001; {p(0.01 versus placebo (ANCOVA on ranks with treatment and region as factors and rank
baseline as covariate). Lehmann point estimate of shift (95% CI): {0.0 (20.5 to 0.0); 120.5 (20.7 to 0.0); "0.0 (0.0 to 0.0); **0.0 (0.0 to 0.0).
ANCOVA, analysis of covariance; CI, confidence interval; CZP, certolizumab pegol; ES, erosion score; ITT, intention-to-treat; JSN, joint space narrowing;
mTSS, modified Total Sharp Scores; MTX, methotrexate.
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these five patients had PPD reactions of 4–5 mm with normal
chest x-ray findings and one patient with a PPD reaction (6 mm)
also had abnormal chest x-ray findings at baseline, which were
deemed not clinically significant by local investigators. These
patients were enrolled into the study by investigator discretion.
The length of time from exposure to certolizumab pegol to
development of tuberculosis ranged from 58 to 169 days. All
patients received treatment for tuberculosis and the study drug
was permanently discontinued in four of the five cases. In one
case, the patient completed the study.
One case of malignant neoplasm was reported in each of the
placebo (bladder cancer), certolizumab pegol 200 mg (testicular
cancer) and certolizumab pegol 400 mg (colon cancer) groups.
Two patients died during the study, one in the certolizumab
pegol 200 mg (myocardial infarction) and one in the 400 mg
(fracture, shock) groups; these events were assessed as unlikely
to be related to the study drug.
Laboratory interference
A prolonged activated partial thromboplastin time (aPTT) was
seen in the 200 mg and 400 mg dose groups of certolizumab
pegol (4.8% and 4.9% of patients, respectively) versus placebo
(1.6%). Additional analyses demonstrated that PEG interferes
with the phospholipid component of some commercial assays
that measure aPTT, including the HemosIL aPTT-SP-liquid
(Instrumentation Laboratory, Lexington, Massachusetts, USA)
and PTT-LA (Diagnostica Stago, Parsippany, New Jersey, USA)
assays used in this trial.
DISCUSSION
This trial demonstrated that certolizumab pegol plus MTX
significantly improved the signs and symptoms of RA, inhibited
progression of joint damage and increased physical function and
quality of life versus placebo plus MTX in patients with active RA
despite MTX. Statistically significant and clinically meaningful
differences between placebo and both certolizumab pegol doses
were observed with respect to the primary end point (ACR20
response) and all secondary end points (including ACR50, ACR70,
ACR core set variables such as swollen and tender joint counts,
changes in DAS28 and DAS28 remission). These clinical benefits
were achieved rapidly, as early as 1 week of treatment, in this
population of patients with severe disease (91% with DAS28 .5.1
at baseline). Although the weekly dosage of MTX used in this trial
was low by US standards, post hoc analyses showed that ACR20/
50/70 response rates at week 24 were similar in patients who
received baseline MTX doses of 10 mg/week, .10–15 mg/week
and .15 mg/week. There were no statistically significant differ-
ences in clinical efficacy on any study primary or secondary end
points between the two certolizumab pegol dose groups, suggest-
ing that a 200 mg dose every 2 weeks is optimal for treatment.
Both doses of certolizumab pegol plus MTX significantly
inhibited the progression of structural joint damage compared
with placebo plus MTX, as demonstrated by significantly lower
mean changes from baseline in mTSS, ES and JSN scores.
Comparable inhibition of progression was seen with both
certolizumab pegol doses and there was some suggestion of repair
of joint damage in the 400 mg dose group (negative 95% CI of the
change inmTSS).
28Anadditionalanalysisof theradiographic data
from patients who withdrew at week 16 owing to ACR20 non-
response (per protocol) found that certolizumab pegol had slowed
the progression of joint damage in these patients even though
they had not achieved an ACR20 response, confirming that
certolizumab pegol rapidly inhibits joint damage. These data are
also in line with previous findings on a dissociation of inflamma-
tion and destruction in the course of anti-TNF plus MTX
treatment.
29 Certolizumab pegol provided rapid, significant and
clinically meaningful improvements in physical function and
quality of life, with significant changes in HAQ-DI at week 1 and
in SF-36 PCS, MCS and PF domains at week 12, which continued
to improve through to week 24. As functional outcomes are
associated with structural damage in progressive RA,
30–32 treat-
ments that can both improve physical function and inhibit joint
damage may help prevent long-term disability. The robustness of
all clinical, radiographic and physical function findings were
confirmed by sensitivity analyses (data not shown).
Certolizumab pegol plus MTX had an acceptable safety
profile with a low incidence of discontinuations due to adverse
events. An isolated increase in aPTT was seen for patients
treated with certolizumab pegol and placebo in this study.
However, no association was seen between increased coagula-
tion assay time and bleeding events. Additional laboratory
analyses have shown that this observation was an in vitro
phenomenon and that there is no effect on in vivo coagulation
function (data not shown). Serious infections, including
tuberculosis, were reported more frequently with certolizumab
pegol than placebo, consistent with rates associated with other
anti-TNF treatments.
33 Tuberculosis was reported in a total of
five patients (all treated with certolizumab pegol) and was
partly attributable to insufficient stringency in screening results
by local investigators combined with high background rates of
tuberculosis.
34 If current criteria were used to screen for
tuberculosis, two of these patients would have been classified
as having positive PPD reactions and would have been excluded
Table 3 Treatment-emergent adverse events (safety population)
Adverse events
Placebo +
MTX
(n=125)*
Certolizumab
pegol 200 mg +
MTX
(n=248)
Certolizumab
pegol 400 mg +
MTX
(n=246)
Any treatment-emergent AE 66 (52.8) 139 (56.0) 125 (50.8)
Intensity
Mild 45 (36.0) 108 (43.5) 101 (41.1)
Moderate 32 (25.6) 61 (24.6) 57 (23.2)
Severe 5 (4.0) 17 (6.9) 14 (5.7)
Related 23 (18.4) 61 (24.6) 56 (22.8)
Any infections 26 (20.8) 69 (27.8) 53 (21.5)
SAE 4 (3.2) 18 (7.3) 18 (7.3)
Serious infections 0 8 (3.2) 6 (2.4)
AE leading to death 0 1 (0.4) 1 (0.4)
AE leading to withdrawal 2 (1.6) 12 (4.8) 7 (2.8)
Most common AE{
Urinary tract infection 9 (7.2) 11 (4.4) 5 (2.0)
Upper respiratory tract
infection
2 (1.6) 11 (4.4) 4 (1.6)
Headache 1 (0.8) 9 (3.6) 8 (3.3)
Bacteriuria 4 (3.2) 8 (3.2) 6 (2.4)
Nasopharyngitis 1 (0.8) 8 (3.2) 4 (1.6)
Rheumatoid arthritis 4 (3.2) 7 (2.8) 2 (0.8)
Hypertension 2 (1.6) 6 (2.4) 9 (3.7)
Haematuria 5 (4.0) 4 (1.6) 4 (1.6)
Hepatic enzyme increased 4 (3.2) 3 (1.2) 3 (1.2)
AST increased 5 (4.0) 2 (0.8) 6 (2.4)
ALT increased 6 (4.8) 1 (0.4) 8 (3.3)
Results are shown as number (%) of patients.
*Two patients in the placebo group received certolizumab pegol 200 mg and were
included in the certolizumab pegol 200 mg group for safety evaluations; {treatment-
emergent adverse events occurring in >3% in any group of the safety population.
AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase;
MTX, methotrexate; SAE, serious adverse event.
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patient in each treatment group), with no reported lymphomas.
One limitation of this study was its relatively short duration.
Longer-term experience, especially related to safety, will need to
be obtained from long-term extension trials and registries.
Nevertheless, the study demonstrates that the efficacy and
safety of certolizumab pegol is consistent with previously
published results for other anti-TNF therapies.
5–7
The three licensed anti-TNF agents are either monoclonal
antibodies (adalimumab, infliximab) or receptor constructs
(etanercept) and all contain an immunoglobulin G Fc portion.
Interestingly, the data shown here show that the Fc portion,
which is lacking in certolizumab pegol, is not necessary for TNF
inhibitors to be clinically effective in RA. Thus, the primary mode
of action of TNF inhibitors in RA does not appear to involve Fc-
mediated effects but rather the binding and inactivation of TNF
and, probably, reverse signalling,
35 36 which can also be mediated
by an Fc-free Fab9 molecule such as certolizumab pegol.
In summary, this study demonstrated that certolizumab pegol
rapidly and significantly ameliorates clinical signs and symptoms
of RA, inhibits progression of structural damage and improves
physical function and quality of life in patients with active RA
despite MTX. These clinical benefits are associated with a low
rate of injection-site reactions and a safety profile consistent with
other anti-TNF therapies. Therefore, certolizumab pegol expands
the treatment armamentarium for patients with RA.
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